Methixene hydrochloride is a synthetic anticholinergic drug with antihistamine and antiemetic properties. It was initially developed as an antipsychotic but is rarely used for this purpose today. Its primary use is in the treatment of motion sickness and other forms of nausea and vomiting. Methixene hydrochloride is thought to work by blocking acetylcholine receptors in the central nervous system, which reduces the activity of the vagus nerve and the parasympathetic nervous system. This effect helps to alleviate symptoms of motion sickness and other types of nausea and vomiting. The compound is synthesized through a series of chemical reactions starting from readily available starting materials. Methixene hydrochloride is studied due to its potential applications in the treatment of various conditions, including motion sickness, Parkinson's disease, and Alzheimer's disease. The compound has also been investigated for its potential use as a muscle relaxant and an anti-inflammatory agent. While methixene hydrochloride has demonstrated some therapeutic benefits, its use is limited due to its potential side effects, including drowsiness, dry mouth, blurred vision, and constipation.'
| ID Source | ID |
|---|---|
| PubMed CID | 71177 |
| CHEMBL ID | 1200426 |
| CHEBI ID | 51025 |
| SCHEMBL ID | 121381 |
| MeSH ID | M0308923 |
| Synonym |
|---|
| nsc-78194 |
| CHEBI:51025 , |
| methixene hydrochloride hydrate |
| methixene hcl |
| methixene hydrochloride |
| 7081-40-5 |
| D01871 |
| methixene hydrochloride hydrete |
| trest (tn) |
| metixene hydrochloride (jan) |
| methixene hydrochloride (usan) |
| sj 1977 |
| nsc 78194 |
| 1-methyl-3-(thioxanthen-9-ylmethyl)piperidine hydrochloride monohydrate |
| methixene hydrochloride monohydrate |
| piperidine, 1-methyl-3-(9h-thioxanthen-9-ylmethyl)-, hydrochloride, monohydrate |
| methixene hydrochloride [usan] |
| CHEMBL1200426 |
| anhydrous metixene hydrochloride |
| sj-1977 |
| metixene hydrochloride anhydrous |
| FT-0657024 |
| A837000 |
| 3-hydroxy-2-(4-methoxyphenyl)chromen-4-one;3-((9h-thioxanthen-9-yl)methyl)-1-methylpiperidine hydrochloride hydrate |
| unii-84l8xk6n1g |
| 84l8xk6n1g , |
| AKOS015855384 |
| 3-((9h-thioxanthen-9-yl)methyl)-1-methylpiperidine hydrochloride hydrate |
| SCHEMBL121381 |
| metixene hydrochloride monohydrate |
| metixene hydrochloride [ep impurity] |
| metixene hydrochloride [ep monograph] |
| metixene hydrochloride [mart.] |
| metixene hydrochloride [jan] |
| methixene hydrochloride [orange book] |
| 1-methyl-3-(9h-thioxanthen-9-ylmethyl)piperidine;hydrate;hydrochloride |
| mfcd00941488 |
| metixene hydrochloride; (rs)-1-methyl-3-[(9h-thioxanthen-9-yl)methyl]piperidine hydrochloride |
| 1-methyl-3-(thioxanthen-9-ylmethyl)-piperidine hydrochloride |
| Q27887706 |
| metixene hydrochloride hydrate |
| 1-methyl-3-[(9h-thioxanthen-9-yl)methyl]piperidine--hydrogen chloride--water (1/1/1) |
| DTXSID00991080 |
| HY-120081A |
| CS-0085190 |
| C76260 |
| 3-((9h-thioxanthen-9-yl)methyl)-1-methylpiperidine hcl hydrate |
| BS-29371 |
| 3-((9h-thioxanthen-9-yl)methyl)-1-methylpiperidinehydrochloridehydrate |
| metixene hydrochloride (ep monograph) |
| metixene hydrochloride (ep impurity) |
| metixene hydrochloride (mart.) |
| Class | Description |
|---|---|
| hydrochloride | A salt formally resulting from the reaction of hydrochloric acid with an organic base. |
| hydrate | An addition compound that contains water in weak chemical combination with another compound. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 10.0000 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| TDP1 protein | Homo sapiens (human) | Potency | 27.5110 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| IDH1 | Homo sapiens (human) | Potency | 20.5962 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| geminin | Homo sapiens (human) | Potency | 0.5805 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.8730 | 10.7219 | 78.4000 | AID493155 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.75) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||